Jin Wang
Greater China Region Guide 2024
Up and Coming : Competition/Antitrust (PRC Firms)
Email address
[email protected]Contact number
+852 3976 8882Share profile
Up and Coming
About
Provided by Jin Wang
Practice Areas
MS. WANG SPECIALIZES IN ANTITRUST LAW, COMPETITION LAW AND REGULATORY MATTERS.
Ms. Wang has more than 10 years of experience in advising clients on all aspects of Chinese competition law, including merger control, administrative investigations, and antitrust compliance. She has advised clients in a broad range of industry sectors, including healthcare, automobiles, chemicals, consumer products and retail, real estate, container shipping, energy and natural resources, high-tech, infrastructure and transportation, and private equity.
Career
Before joining the firm, Ms. Wang worked in the Beijing office of a leading international law firm for five years.
Languages Spoken
-Chinese
-English
Education
Peking University School of Law
LL.M
Renmin University of China Law School
LL.B
Experience
Antitrust investigation
Advised an international pharmaceutical manufacturer on antitrust issues in its proposed cooperation with an online diagnostics and pharmaceutical distribution business
Advised Eastman Chemical Company, a global manufacturer of chemical products, on the first abuse of dominance investigation initiated by the SAIC in the industry, as well as on an NDRC investigation into resale price maintenance
Advised three state-owned port groups (Tianjin Port, Dalian Port and Yantian Port) on reaching favorable results in an NDRC antitrust investigation into alleged abuses of dominance
Advised Medtronic, a multinational medical device company, in successfully obtaining reduced fines in an NDRC investigation
Advised Chrysler, Daimler and Chang’an Ford in successfully obtaining reduced fines in three out of the five published NDRC resale price maintenance cases against multinational automobile companies
Advised three multinational automobile companies in similar resale price maintenance investigations initiated by the NDRC
Advised a leading global high-tech company in handling an SAIC antitrust investigation
Advised Höegh Autoliners, an international shipping company, on the first successful defense against an NDRC cartel investigation in the PRC
Advised a leading US toy manufacturing company on its defense against allegations by the local competition law enforcement that the company breached the PRC Anti-unfair Competition Law
Advised a leading Swiss medical device manufacturer on responding to allegations of abuse of dominant position in China
Advised several multinational and Chinese domestic manufacturing companies on antitrust issues arising from their cooperation and distribution agreements
Advised a multinational pharmaceutical company and several state-owned company groups in setting up their internal antitrust compliance programs
Merger control
Advised Danaher on the PRC merger filing for its USD 21.4 billion acquisition of GE Healthcare Life Sciences’ Biopharma Business
Advised Blackstone on its acquisitions of real estate in China and its recent acquisition of real estate assets in Japan
Advised Warburg Pincus LLC on the PRC merger control filing for its acquisition of shares of P&D Investment Holding Limited
Advised Mylan on its acquisition of Sebivo from Novartis
Advised DKSH on the acquisition of DKSH’s pharmaceutical distribution business in China by Warburg Pincus LLC
Advised Hyundai Motor Company on its joint venture with Aptiv PLC to develop autonomous driving technology
Advised Beijing Mercedes-Benz Sales Service Co., Ltd. (BMBS) on the acquisition of the distribution business of Denza through contractual arrangement
Advised TPG on the investment in APM Monaco by a consortium led by TPG
Advised TPG on its acquisition of Genting’s Dream Cruises business
Advised GE on its joint venture with Chaowei Power Holdings Limited to market a sodium-nickel-chloride battery
Advised Chindex on its PRC merger control filing for the USD 461 million takeover of Chindex by a group led by private equity firm TPG and Shanghai Fosun Pharmaceutical
Advised CNPC on its PRC merger control filing for its acquisition of a Russian energy company
Advised Daimler AG on its PRC merger control filing for its carbon-fiber reinforced plastic components manufacturing joint venture with Toray and ACE and on its other antitrust matters
Advised Daimler AG and Robert Bosch on its PRC merger control filing for their joint venture for manufacturing electric motors for electric vehicles and hybrid electric vehicles
Advised Davidson Kempner, GLG Partners, Centaurus Capital and Senrigan Capital on PRC merger control analysis
Advised Eni S.p.A. and Rosneft Oil Company on the PRC merger control filing for their joint venture for the exploration of oil and gas and for the development, production and marketing of oil and gas products
Advised Mahle on the PRC merger control filing for its acquisition of Behr
Advised UGL on the PRC merger control filing for the sale of shares in DTZ to TPG
Advised Virgin Atlantic Airlines on its PRC merger control filing for its joint venture with Delta Airlines
Advised United Technologies Corporation on various issues under the PRC Anti-Monopoly Law in its proposed acquisition in China